Skip to content

Lifestyle Intervention for Senior Diabetics

Lifestyle Intervention Strategy to Treat Diabetes in Older Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02348801
Acronym
LISD
Enrollment
100
Registered
2015-01-28
Start date
2015-01-31
Completion date
2020-12-31
Last updated
2021-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Diabetes Mellitus, Overweight

Brief summary

Older people with diabetes will be assigned to the 1-year lifestyle program or no lifestyle program while continuing usual treatment for diabetes. The lifestyle program will consist of teaching how to practice healthy diet and regular exercise at our facility and continued into the community and home. It is hoped that the results would provide convincing proof about the usefulness of lifestyle change in older patients with diabetes.

Detailed description

Background: Hypothesis: Lifestyle intervention will be highly successful in the population of older adults with diabetes, with resultant significant improvement in glycemic metabolic control mediated by improved insulin action/secretion, accompanied by significant improvements in physical function, cognitive function, and quality-of-life (QOL). Rationale: Countering the prevailing notion that it is difficult to change lifelong habits, the PI has ample preliminary data showing successful lifestyle change in older adults. A similar lifestyle intervention augmented by motivational interviewing might also be successful in older adults with diabetes with eventual translation to the community- and home-settings. Aims: In older adults with diabetes and comorbidities, the aims are to: determine the effect of lifestyle intervention on glycemic metabolic control, determine the mechanisms underlying lifestyle-induced changes in glucose homeostasis, and determine the effect of lifestyle intervention on age-relevant health outcomes: physical function, cognitive function, QOL. Design: Older adults with diabetes and comorbidities will be randomized to center-based lifestyle intervention continued into the community and home vs. healthy-lifestyle control for 1 year. Relevance to diabetes prevention and treatment: Data from a randomized-controlled trial will provide high-level evidence to convince practitioners to implement lifestyle intervention as the primary therapy for diabetes in older patients.

Interventions

Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement. Exercise sessions of \ 90 min duration 15 min warm-up of flexibility exercise, followed by \ 30 min of aerobic exercise, and, after a brief rest period, \ 30 min of resistance training, and finally \ 15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months.

BEHAVIORALHealthy lifestyle

Diabetes support and education

Sponsors

American Diabetes Association
CollaboratorOTHER
Michael E. DeBakey VA Medical Center
CollaboratorFED
Biomedical Research Institute of New Mexico
CollaboratorOTHER
Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subjects will be older (age 65-85 years) adults with type 2 diabetes. Diabetes will be determined by self-report with verification (medical records, current treatment, confirmation from health care provider, fasting glucose ≥126 mg/dL, symptoms of hyperglycemia with plasma glucose ≥200 mg/dL or 2-hour plasma glucose ≥200 mg/dL after a 75-g glucose load on at least two occasions, or HbA1C of ≥ 6.5%. All subjects will have a BMI of ≥ 27 kg/m2 and have stable weight (±2 kg) and on stable medications during the last 6 mos.

Exclusion criteria

* Volunteers will be excluded if they fail to provide informed consent, have any major comorbid disease that is uncontrolled, or any condition that is likely to limit life span and/or affect the safety of the interventions, or interfere with the conduct of the trial. Examples include: 1) unstable cardiopulmonary disease (e.g. recent MI, unstable angina, stroke within past 3 months) or unstable disease (e.g. Class IV congestive heart failure: 2) severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, amyotrophic lateral sclerosis, active rheumatoid arthritis), 3) significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State exam (i.e. MMSE score \<24),43 4) cancer requiring treatment in the past 5 years, 5) documented history of pulmonary embolism in the past 6 months, 6) positive exercise stress test for cardiac ischemia, and 7) HbA1c \>11%.

Design outcomes

Primary

MeasureTime frame
Change in hemoglobin A1cbaseline and 12 months

Secondary

MeasureTime frame
Change in bone mineral densitybaseline and 12 months
Change in bone metabolismbaseline and 12 months
Change in bone qualitybaseline and 12 months
Change in composite cognitive scorebaseline and 12 months
Change in insulin sensitivitybaseline and 12 months
Change in insulin secretionbaseline and 12 months
Change in fasting glucosebaseline and 12 months
Change in adipocytokines and hormonesbaseline and 12 months
Change in peak aerobic powerbaseline and 12 months
Change in cardiometabolic risk profilebaseline and 12 months
Change in the modified physical performance testbaseline and 12 months
Change in fat mass and visceral fatbaseline and 12 months
Change in quality of lifebaseline and 12 months
Change in health care utilizationbaseline and 12 months
Change in the modified mini-mental state exambaseline and six months
Change in muscle strength and qualitybaseline and 12 months
Change in gait speedbaseline and 12 months
Change in stroop color namingbaseline and 12 months
Change in word list fluencybaseline and 12 months
Change in ray auditory verbal learning testbaseline and 12 months
Change in Trail A./Bbaseline and 12 months
Change in Lean body massbaseline and 12 months
Change in composite cognitive z-scorebaseline and 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026